Nrf2 gene promoter polymorphism is associated with ulcerative colitis in a Japanese population

Hepato-Gastroenterology

Volumn 55, Issue 82-83, 2008, Pages 394-397

  Arisawa, Tomiyasu ^a,b   Tahara, Tomomitsu ^a   Shibata, Tomoyuki ^a   Nagasaka, Mitsuo ^a   Nakamura, Masakatsu ^a   Kamiya, Yoshio ^a   Fujita, Hiroshi ^a   Yoshioka, Daisuke ^a   Okubo, Masaaki ^a   Sakata, Mikiju ^a   Wang, Fang Yu ^a   Hirata, Ichiro ^a   Nakano, Hiroshi ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE   (Japan)

Author keywords

Nuclear factor erythroid 2 related factor 2; Promoter polymorphism; Ulcerative colitis

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; DNA EXTRACTION; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOTE; HUMAN; HUMAN GENOME; JAPANESE; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; TRANSCRIPTION FACTOR NRF2 GENE; ULCERATIVE COLITIS;

ADULT; COLITIS, ULCERATIVE; FEMALE; HUMANS; JAPAN; MALE; NF-E2-RELATED FACTOR 2; POLYMORPHISM, GENETIC;

EID: 44349119778     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Head KA, Jurenka JS: Inflammatory bowel disease part I: Ulcerative colitis-pathophysiology and conventional and alternative treatment options. Altern Med Rev 2003; 8:247-283.
2. Blumberg RS, Strober W: Prospects for research in inflammatory bowel diseases. JAMA 2001; 285:643-647.
3. Mahida YR, Ceska M, Effenberger F, Kurlak L, Lindley I, Hawkey CJ: Enhanced synthesis of neutrophil-activating peptide-1/interleukin-8 in active ulcerative colitis. Clin Sci (Lond.) 1992; 82:273-275.
4. MacDonald TT, Murch SH: Aetiology and pathogenesis of chronic inflammatory bowel disease. Baillieres Clin Gastroenterol 1994; 8:1-34.
5. Lakatos PL, Fischer S, Lakatos L, Gal I, Papp J: Current concept on the pathogenesis of inflammatory bowel disease-crosstalk between genetic and microbial factors: Pathogenic bacteria and altered bacterial sensing or changes in mucosal integrity take "toll"? World J Gastroenterol 2006; 12:1829-1841.
6. Annese V, Valvano MR, Palmieri O, Latiano A, Bossa F, Andriulli A: Multidrug resistance 1 gene in inflammatory bowel disease: a meta-analysis. World J Gastroenterol 2006; 12:3636-3644.
7. Jiang Y, Xia B, Jiang L, et al: Association of CTLA-4 gene microsatellite polymorphism with ulcerative colitis in Chinese patients. Inflamm Bowel Dis 2006; 12:369-373.
8. Castro-Santos P, Suarez A, Lopez-Rivas L, Mozo L, Gutierrez C: TNFalpha and IL-10 gene polymorphisms in inflammatory bowel disease. Association of -1082 AA low producer IL-10 genotype with steroid dependency. Am J Gastroenterol 2006; 101:1039-1047.
9. Pierik M, Joossens S, Van Steen K, et al: Toll-like receptor-1, -2, and -6 polymorphisms influence disease extension in inflammatory bowel diseases. Inflamm Bowel Dis 2006; 12:1-8.
10. Takagawa T, Tamura K, Takeda N, et al: Association between IL-18 gene promoter polymorphisms and inflammatory bowel disease in a Japanese population. Inflamm Bowel Dis 2005; 11:1038-1043.
11. Torok HP, Glas J, Tonenchi L, Mussack T, Folwaczny C: Polymorphisms of the lipopolysaccharide-signaling complex in inflammatory bowel disease: association of a mutation in the Toll-like receptor 4 gene with ulcerative colitis. Clin Immunol 2004; 112:85-91.
12. Obana N, Takahashi S, Kinouchi Y, et al: Ulcerative colitis is associated with a promoter polymorphism of lipopolysaccharide receptor gene, CD14. Scand J Gastroenterol 2002; 37:699-704.
13. Pravda J: Radical induction theory of ulcerative colitis. World J Gastroenterol 2005; 11:2371-2384.
14. Burdon RH: Superoxide and hydrogen peroxide in relation to mammalian cell proliferation. Free Radic Biol Med 1995; 18:775-794.
15. Lih-Brody L, Powell SR, Collier KP, et al: Increased oxidative stress and decreased antioxidant defenses in mucosa of inflammatory bowel disease. Dig Dis Sci 1996; 41:2078-2086.
16. Ishii T, Itoh K, Takahashi S, Sato H, et al: Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. J Biol Chem 2000; 275:16023-16029.
17. Yamamoto T, Yoh K, Kobayashi A, et al: Identification of polymorphisms in the promoter region of the human NRF2 gene. Biochem Biophys Res Commun 2004; 321:72-79.
18. Arisawa T, Tahara T, Shibata T, et al: The relationship between Helicobacter pylori infection and promoter polymorphism of the Nrf2 gene in chronic gastritis. Int J Mol Med 2007; 19:143-148.
19. Podolsky DK: Inflammatory bowel disease 2. N Engl J Med 1991; 325:928-937.
20. Satsangi J, Parkes M, Louis E, et al: Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12. Nat Genet 1996; 14:199-202.
21. Chan K, Kan YW: Nrf2 is essential for protection against acute pulmonary injury in mice. Proc Natl Acad Sci USA 1999; 96:12731-12736.
22. Enomoto A, Itoh K, Nagayoshi E, et al: High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes. Toxicol Sci 2001; 59:169-177.
23. Aoki Y, Sato H, Nishimura N, Takahashi S, Itoh K, Yamamoto M: Accelerated DNA adduct formation in the lung of the Nrf2 knockout mouse exposed to diesel exhaust. Toxicol Appl Pharmacol 2001; 173:154-160.
24. Ramos-Gomez M, Kwak MK, Dolan PM, et al: Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc Natl Acad Sci USA 2001; 98:3410-3415.
25. Cho HY, Jedlicka AE, Reddy SP, et al: Role of NRF2 in protection against hyperoxic lung injury in mice. Am J Respir Cell Mol Biol 2002; 26:175-182.
26. Mogadam M, Korelitz BI, Ahmed SW, Dobbins WO 3rd, Baiocco PJ: The course of inflammatory bowel disease during pregnancy and postpartum. Am J Gastroenterol 1981; 75:265-269.
27. Boyko EJ, Theis MK, Vaughan TL, Nicol-Blades B: Increased risk of inflammatory bowel disease associated with oral contraceptive use. Am J Epidemiol 1994; 140(3):268-278.
28. Ansell PJ, Espinosa-Nicholas C, Curran EM, et al: In vitro and in vivo regulation of antioxidant response element-dependent gene expression by estrogen. Endocrinology 2004; 145:311-317.
29. Ansell PJ, Lo S-C, Newton LG, et al: Repression of cancer pretective genes by 17-estradiol: Ligand-dependent interaction between human Nrf2 and estrogen receptor-α. Mol Cell Endocrinol 2005; 243:27-34.